Your True Blue Savings Card does more than just help eligible patients save money on Mitigare® (colchicine)—it also gives adult patients access to a number of free services. These are the services available:

Mitigare® Home Delivery

To request Mitigare® (colchicine) home delivery, simply print and complete the Patient Information and Insurance Information sections of the Mitigare® CompleteCare Home Delivery Form. Then, bring the form to your doctor to complete and submit on your behalf. Start here…

 

Automatic Refill Program

Patients enrolled in Home Delivery have the option of selecting Automatic Refills. As an enrolled member, approximately 10 days before your refill is shipped, you will receive a reminder that it is time for a refill. Confirm the refill request and the order will be shipped to your door. Or, cancel the refill at your disclosure. Learn more…

 

Refill Reminders

Refill Reminders are available through the Mitigare® Home Delivery program. You can choose to receive refill reminders via your preferred method of communication — an automated phone call, email or text message. To have your prescription refilled right away, simply respond “yes” to your reminder message. Sign-up now…

 

Find a Pharmacy

There are three ways to find a pharmacy in your area to fill your prescription. Start here…

 

Savings Offers & More

Patients and healthcare professionals can access support and savings information from 8 am to 7 pm Monday through Friday (EST). Benefits include Mitigare® Savings Card activation, determination of the prescription co-pay, Find a Pharmacy Service, Mitigare® Home Delivery enrollment, and access to product information. Discover more…

 

Patient Resources

A variety of patient support and educational materials are at your fingertips for viewing and downloading. Find them here…

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.